Genetic evidence that intratumoral t-cell proliferation and activation are associated with recurrence and survival in patients with resected colorectal liver metastases

Cancer Immunology Research

Volumn 3, Issue 4, 2015, Pages 380-388

  Maker, Ajay V ^a,b   Ito, Hiromichi ^a   Mo, Qianxing ^a   Weisenberg, Elliot ^b   Qin, Li Xuan ^a   Turcotte, Simon ^a   Maithel, Shishir ^a   Shia, Jinru ^a   Blumgart, Leslie ^a   Fong, Yuman ^a   Jarnagin, William R ^a   De Matteo, Ronald P ^a   D'Angelica, Michael I ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARCINOEMBRYONIC ANTIGEN; HERPESVIRUS ENTRY MEDIATOR LIGAND; INTERLEUKIN 10; INTERLEUKIN 18; TNFSF14 PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL LIVER METASTASIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROLYMPHOCYTE; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; T LYMPHOCYTE ACTIVATION; TUMOR MICROENVIRONMENT; CELL PROLIFERATION; COLORECTAL TUMOR; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; KAPLAN MEIER METHOD; LIVER NEOPLASMS; LYMPHOCYTE ACTIVATION; METABOLISM; MIDDLE AGED; PROCEDURES; RECURRENT DISEASE; RETROSPECTIVE STUDY; SECONDARY; SURVIVAL ANALYSIS; TISSUE MICROARRAY; TUMOR ASSOCIATED LEUKOCYTE;

BIOMARKERS, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; NEOPLASM PROTEINS; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; TUMOR MICROENVIRONMENT; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 14;

EID: 84962233504     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-14-0212     Document Type: Article

References (53)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Leonard GD, Brenner B, Kemeny NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2005;23:2038-48.
3. Steele G Jr, Ravikumar TS. Resection of hepatic metastases from colorectal cancer: biologic perspectives. Ann Surg 1989;210:127-38.
4. Bismuth H, Adam R, Levi F, Farabos C, Waechter F, Castaing D, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996;224:509-22.
5. Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 2007;25:4575-80.
6. Chiba T, Ohtani H, Mizoi T, Naito Y, Sato E, Nagura H, et al. Intraepithelial CD8+ T-cell-count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: possible association with suppression of micrometastasis. Br J Cancer 2004;91:1711-7.
7. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-4.
8. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005;353:2654-66.
9. Prall F, Duhrkop T, Weirich V, Ostwald C, Lenz P, Nizze H, et al. Prognostic role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. Hum Pathol 2004;35:808-16.
10. Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998;58:3491-4.
11. Katz SC, Pillarisetty V, Bamboat ZM, Shia J, Hedvat C, Gonen M, et al. Tcell infiltrate predicts long-term survival following resection of colorectal cancer liver metastases. Ann Surg Oncol 2009;16:2524-30.
12. Katz SC, Bamboat ZM, Maker AV, Shia J, Pillarisetty VG, Yopp AC, et al. Regulatory T cell infiltration predicts outcome following resection of colorectal cancer liver metastases. Ann Surg Oncol 2013;20:946-55.
13. Yu P, Fu YX. Targeting tumors with LIGHT to generate metastasis-clearing immunity. Cytokine Growth Factor Rev 2008;19:285-94.
14. Yu P, Lee Y, Liu W, Chin RK, Wang J, Wang Y, et al. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol 2004;5:141-9.
15. Hyatt G, Melamed R, Park R, Seguritan R, Laplace C, Poirot L, et al. Gene expression microarrays: glimpses of the immunological genome. Nat Immunol 2006;7:686-91.
16. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg 1999;230:309-21.
17. Schroeder A, Mueller O, Stocker S, Salowsky R, Leiber M, Gassmann M, et al. The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol 2006;7:3.
18. Ito H, Mo Q, Qin LX, Viale A, Maithel SK, Maker AV, et al. Gene expression profiles accurately predict outcome following liver resection in patients with metastatic colorectal cancer. PLoS One 2013;8:e81680.
19. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003;19:185-93.
20. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000;25:25-9.
21. Hosack DA, Dennis G Jr, Sherman BT, Lane HC, Lempicki RA. Identifying biological themes within lists of genes with EASE. Genome Biol 2003;4: R70.
22. Cui X, Churchill GA. Statistical tests for differential expression in cDNA microarray experiments. Genome Biol 2003;4:210.
23. Budczies J, Klauschen F, Sinn BV, Gyorffy B, Schmitt WD, Darb-Esfahani S, et al. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS One 2012;7:e51862.
24. Qin JZ, Upadhyay V, Prabhakar B, Maker AV. Shedding LIGHT (TNFSF14) on the tumor microenvironment of colorectal cancer liver metastases. J Transl Med 2013;11:70.
25. Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004;239:818-27.
26. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
27. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013-9.
28. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17.
29. Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996;77: 1303-10.
30. Diederichsen ACP, Hjelmborg JVB, Christensen PB, Zeuthen J, Fenge C. Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells. Cancer Immunol Immunother 2003;52:423-8.
31. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005;102:18538-43.
32. Zhang L. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-13.
33. Katz S, Maker AV, Pillarisetty V, et al. Colorectal cancer liver metastases T cell subset counts and ratios are independent predictors of outcome. Ann Surg Oncol 2011;18:S13.
34. Marrack P, Mitchell T, Hildeman D, Kedl R, Teague TK, Bender J, et al. Genomic-scale analysis of gene expression in resting and activated T cells. Curr Opin Immunol 2000;12:206-9.
35. Teague TK, Hildeman D, Kedl RM, Mitchell T, Rees W, Schaefer BC, et al. Activation changes the spectrum but not the diversity of genes expressed by T cells. Proc Natl Acad Sci U S A 1999;96:12691-6.
36. Ochs MF, Peterson AJ, Kossenkov A, Bidaut G. Incorporation of gene ontology annotations to enhance microarray data analysis. Methods Mol Biol 2007;377:243-54.
37. Werner T. Bioinformatics applications for pathway analysis of microarray data. Curr Opin Biotechnol 2008;19:50-4.
38. Bard JB, Rhee SY. Ontologies in biology: design, applications and future challenges. Nat Rev Genet 2004;5:213-22.
39. Granger SW, Ware CF. Turning on LIGHT. J Clin Invest 2001;108:1741-2.
40. Harrop JA, McDonnell PC, Brigham-Burke M, Lyn SD, Minton J, Tan KB, et al. Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth. J Biol Chem 1998;273:27548-56.
41. Tamada K, Shimozaki K, Chapoval AI, Zhai Y, Su J, Chen SF, et al. LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response. J Immunol 2000;164: 4105-10.
42. Shaikh RB, Santee S, Granger SW, Butrovich K, Cheung T, Kronenberg M, et al. Constitutive expression of LIGHT on T cells leads to lymphocyte activation, inflammation, and tissue destruction. J Immunol 2001;167: 6330-7.
43. Wang J, Lo JC, Foster A, Yu P, Chen HM, Wang Y, et al. The regulation of T cell homeostasis and autoimmunity by T cell-derived LIGHT. J Clin Invest 2001;108:1771-80.
44. Wang Y, Zhu M, Yu P, Fu YX. Promoting immune responses by LIGHT in the face of abundant regulatory T cell inhibition. J Immunol 2010; 184:1589-95.
45. Mingueneau M, Sansoni A, Gregoire C, Roncagalli R, Aguado E, Weiss A, et al. The proline-rich sequence of CD3epsilon controls T cell antigen receptor expression on and signaling potency in preselection CD4+CD8+ thymocytes. Nat Immunol 2008;9:522-32.
46. Halama N, Michel S, Kloor M, Zoernig I, Benner A, Spille A, et al. Localization and density of immune cells inthe invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res 2011;71:5670-7.
47. Gardini A, Ercolani G, Riccobon A, Ravaioli M, Ridolfi L, Flamini E, et al. Adjuvant, adoptive immunotherapy with tumor infiltrating lymphocytes plus interleukin-2 after radical hepatic resection for colorectal liver metastases: 5-year analysis. J Surg Oncol 2004;87:46-52.
48. Grem JL, Jordan E, Robson ME, Binder RA, Hamilton JM, Steinberg SM, et al. Phase II study of fluorouracil, leucovorin, and interferon alfa-2a in metastatic colorectal carcinoma. J Clin Oncol 1993;11:1737-45.
49. Koda K, Glassy MC, McKnight ME, Yasutomi J, Saito N, Dan M, et al. Immunotherapy for recurrent colorectal cancers with human monoclonal antibody SK-1. Anticancer Res 2001;21:621-7.
50. Lygidakis NJ, Sgourakis G, Vlachos L, Raptis S, Safioleas M, Boura P, et al. Metastatic liver disease of colorectal origin: the value of locoregional immunochemotherapy combined with systemic chemotherapy following liver resection. Results of a prospective randomized study. Hepatogas troenterology 2001;48:1685-91.
51. Speetjens FM, Kuppen PJ, Welters MJ, Essahsah F, Voet van den Brink AM, Lantrua MG, et al. Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin Cancer Res 2009;15:1086-95.
52. Van Cutsem E, Siena S, Humblet Y, Canon JL, Maurel J, Bajetta E, et al. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol 2008;19:92-8.
53. Maker AV, Attia P, Rosenberg SA. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol 2005;175:7746-54.